Gain Therapeutics, Inc. (GANX): Nasdaq/NYSE listing notice — Gain Therapeutics receives and cures Nasdaq MVLS deficiency within days

Gain Therapeutics, Inc.

Received Nasdaq MVLS deficiency notice on Jan 8, 2025 for falling below $50M minimum from Nov 14 to Dec 27, 2024.
Regained compliance as of Jan 14, 2025; Nasdaq confirmed compliance in writing on Jan 15, 2025.
No immediate impact on listing; common stock continues trading on Nasdaq Global Market under GANX.
Deficiency was cured within one week; matter is now closed.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Gain Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

um of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The MVLS Deficiency Notice had no immediate effect on the listing of t

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Gain Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

f The Nasdaq Stock Market (“Nasdaq”) notifying the Company that that from November 14, 2024 to December 27, 2024, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The MVLS Deficiency Notice had no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Global Market under the symbol “GANX.” As of January 14, 2025, the Company has regained compliance

View on SEC.gov

Browse all listing & compliance notices →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-003801

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.